Detailed Narrative
Expansion Drag Hits Short-Term Margins
KIMS is currently in a heavy investment phase, having commissioned 4-5 new hospitals in the last year. This expansion added nearly 3,000-4,000 beds of capacity, which management expects to ramp up over the next 4-5 years. While revenue grew 23.3% YoY to ₹965 crores, EBITDA margins fell to 21.6% as these new units are currently EBITDA negative, losing between ₹20-30 crores each. Management maintains that these assets will reach breakeven within 12 months of commissioning.
Thane and Bangalore Lead the Recovery
The Thane unit is showing strong early traction, with 80-90 beds occupied in October and a breakeven target of ₹15 crores monthly revenue expected within the next two months. In Bangalore, the Mahadevapura facility is already performing ahead of expectations, completing its first liver transplant within 45 days. The PES Bangalore unit is awaiting final licensing, with commissioning expected in December 2025, which should further bolster the Karnataka cluster's performance.
ARPOB Expansion Strategy
Management has laid out a clear path to increase ARPOB from the current ₹42,016 to ₹50,000 over the next 8 quarters. This growth will be driven by the scaling of high-ARPOB markets like Thane and Bangalore, where current ARPOBs are already in the ₹50,000-70,000 range. As these units contribute a larger share of consolidated revenue, the overall average is expected to lift significantly, alongside a shift toward more complex specialties like oncology and transplants.
Core Cluster Resilience
The core clusters in Telangana and Andhra Pradesh remain the bedrock of the company's financials. The Andhra cluster reported a strong 28% EBITDA margin in the September quarter, with management guiding for a sustainable range of 25-28%. In Telangana, while occupancy appeared low at 50%, this was attributed to the ongoing rehabilitation of 300 beds at the flagship Secunderabad unit. Once completed, and with the new 550-bed Kondapur expansion coming online in Q1 FY27, the cluster is expected to return to high single-digit growth.
Regulatory and Payer Mix Dynamics
A key headwind in the Nashik market has been the delay in obtaining the CGHS license, which is critical as 35-40% of the market business comes from CGHS and related parties. Currently, Nashik is operating on 70% cash revenue. Conversely, the company expects a 20% price hike benefit on its existing CGHS business in other clusters, which should contribute ₹10-12 crores of incremental EBITDA in FY27, helping offset some of the margin pressure from new hospital losses.